Dimezine Contraindications

Hypersensitivity to the active substances, diphenhydramine or other antihistamines of similar structure or to any of the excipients.
Diphenhydramine is completely excreted renally, and patients with severe renal impairment were excluded from the clinical development programme. Cinnarizine & Dimenhydrinate combination should not be used by patients with a creatinine clearance of ≤ 25 ml/min (severe renal impairment).
Since both active components of Cinnarizine & Dimenhydrinate combination are extensively metabolised by hepatic cytochrome P450 enzymes, the plasma concentrations of the unchanged drugs and their half-lives will increase in patients with severe hepatic impairment. This has been shown for diphenhydramine in patients with cirrhosis. Cinnarizine & Dimenhydrinate combination should therefore not be used by patients with severe hepatic impairment.
Cinnarizine & Dimenhydrinate combination should not be used in patients with angle-closure glaucoma, convulsions, suspicion of raised intracranial pressure, and alcohol abuse or urine retention due to urethroprostatic disorders.